title: Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.
abstract: OBJECTIVE
  Levodopa dose per kilogram body weight is reported to be a significant factor for dyskinesia in Parkinson's disease. We have investigated this hypothesis in data from the studies comparing ropinirole versus levodopa as the initial therapy.
  
  
  METHODS
  Data from the ropinirole versus levodopa studies 056 and REAL-PET in early Parkinson's disease were pooled and manipulated to calculate levodopa dose per kilogram body weight. Logistic regression analysis was performed to investigate significant variables for the development of dyskinesia. Only the patients on levodopa monotherapy or with ropinirole were analyzed.
  
  
  RESULTS
  Analysis of levodopa therapy patients revealed that dyskinetic patients had received significantly higher absolute levodopa dose and levodopa dose per kilogram body weight. Logistic regression revealed that the most significant factor was the higher levodopa dose per kilogram body weight, P = 0.005, odds ratio 1.078, 95% CI 1.023-1.135; younger age was the second factor -P = 0.026. Variables of gender, absolute levodopa dose, weight, disease duration and initial motor Unified Parkinson's disease rating score were not significant.
  
  
  CONCLUSIONS
  Higher levodopa dose per kilogram body weight is an independently significant factor for developing dyskinesia. This relationship should be considered in treatment of Parkinson's disease patients aiming to prevent and manage dyskinesia.
authors: Newark Hospital, Newark, UK. jagdish.sharma@sfh-tr.nhs.uk
authors: J C
authors: JC
authors: Sharma
authors: I N
authors: IN
authors: Ross
authors: O
authors: O
authors: Rascol
authors: D
authors: D
authors: Brooks
mesh_terms: D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D049628:Body Size / Q000502:physiology; D001835:Body Weight / Q000502:physiology*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects; D007980:Levodopa / Q000009:adverse effects*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000978:Antiparkinson Agents; D007211:Indoles; C046649:ropinirole; D007980:Levodopa